JP2015523328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523328A5 JP2015523328A5 JP2015511443A JP2015511443A JP2015523328A5 JP 2015523328 A5 JP2015523328 A5 JP 2015523328A5 JP 2015511443 A JP2015511443 A JP 2015511443A JP 2015511443 A JP2015511443 A JP 2015511443A JP 2015523328 A5 JP2015523328 A5 JP 2015523328A5
- Authority
- JP
- Japan
- Prior art keywords
- ctla
- polypeptide
- amino acid
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 21
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 21
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 21
- 229920001184 polypeptide Polymers 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 238000000034 method Methods 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 102000054189 human CD80 Human genes 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 2
- 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 102000049849 human CD86 Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261645686P | 2012-05-11 | 2012-05-11 | |
| US61/645,686 | 2012-05-11 | ||
| PCT/US2013/030179 WO2013169338A1 (en) | 2012-05-11 | 2013-03-11 | Ctla-4 variants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015523328A JP2015523328A (ja) | 2015-08-13 |
| JP2015523328A5 true JP2015523328A5 (enExample) | 2016-03-31 |
| JP6228971B2 JP6228971B2 (ja) | 2017-11-08 |
Family
ID=49551120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511443A Active JP6228971B2 (ja) | 2012-05-11 | 2013-03-11 | Ｃｔｌａ−４バリアント |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9884902B2 (enExample) |
| EP (2) | EP3207938B1 (enExample) |
| JP (1) | JP6228971B2 (enExample) |
| KR (1) | KR102133060B1 (enExample) |
| CN (2) | CN104302309B (enExample) |
| AU (1) | AU2013260172B2 (enExample) |
| BR (1) | BR112014026718B1 (enExample) |
| CA (1) | CA2868748C (enExample) |
| DK (1) | DK3207938T3 (enExample) |
| ES (1) | ES2777778T3 (enExample) |
| HK (1) | HK1209644A1 (enExample) |
| HU (1) | HUE048925T2 (enExample) |
| MX (2) | MX355234B (enExample) |
| PL (1) | PL3207938T3 (enExample) |
| RU (1) | RU2671465C2 (enExample) |
| SG (2) | SG10201609447XA (enExample) |
| WO (1) | WO2013169338A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4119857A1 (de) | 1991-06-17 | 1992-12-24 | Basf Lacke & Farben | Ueberzugsmittel auf der basis von carboxylgruppenhaltigen polymeren und epoxidharzen |
| ES2777778T3 (es) * | 2012-05-11 | 2020-08-06 | Medimmune Ltd | Variantes de CTLA-4 |
| ES2753150T3 (es) * | 2012-06-29 | 2020-04-07 | Bristol Myers Squibb Co | Métodos para reducir la agregación de glucoproteínas |
| US9944689B2 (en) * | 2013-03-07 | 2018-04-17 | The General Hospital Corporation | Human CTLA4 mutants and use thereof |
| JP2017508446A (ja) * | 2014-01-28 | 2017-03-30 | 北京韓美薬品有限公司 | 二機能性融合タンパク質及びその製造方法並びに使用 |
| EP3733696A1 (en) * | 2015-01-13 | 2020-11-04 | City of Hope | Ctla4-binding protein peptide-linker masks |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| RS61943B1 (sr) | 2015-04-17 | 2021-07-30 | Alpine Immune Sciences Inc | Imunomodulatorni proteini sa prilagodljivim afinitetima |
| WO2017034244A1 (ko) * | 2015-08-21 | 2017-03-02 | 한양대학교 산학협력단 | 중추신경계 질환에 대한 예방 또는 치료효과를 갖는 펩타이드 및 이를 유효성분으로 하는 중추신경계 질환 예방 및 치료용 약학적 조성물 |
| US11351224B2 (en) | 2015-08-21 | 2022-06-07 | Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) | Pharmaceutical composition for preventing and treating transplant rejection |
| EP3336100B1 (en) | 2015-08-21 | 2021-01-13 | IUCF-HYU (Industry-University Cooperation Foundation Hanyang University) | Peptide having effect of preventing or treating central nervous system diseases and pharmaceutical composition for preventing and treating central nervous system diseases, containing same as active ingredient |
| EA201890729A1 (ru) * | 2015-09-14 | 2018-09-28 | Элпайн Имьюн Сайнс, Инк. | Настраиваемые варианты доменов суперсемейства иммуноглобулинов и терапия сконструированными клетками |
| JP6955507B2 (ja) | 2015-12-14 | 2021-10-27 | マクロジェニクス，インコーポレーテッド | Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法 |
| KR101918456B1 (ko) * | 2015-12-15 | 2018-11-16 | 앱클론(주) | Cd80 및 cd86에 특이적으로 결합하는 항체 |
| MX2018012472A (es) | 2016-04-15 | 2019-08-12 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
| IL310729A (en) | 2016-04-15 | 2024-04-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins that are variants of CD80 and their uses |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| EP3596114A2 (en) | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| JP2020511144A (ja) | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用 |
| SG10202111207TA (en) | 2017-05-24 | 2021-11-29 | Als Therapy Development Inst | Therapeutic anti-cd40 ligand antibodies |
| WO2019074983A1 (en) * | 2017-10-10 | 2019-04-18 | Alpine Immune Sciences, Inc. | CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF |
| JP7282760B2 (ja) | 2017-10-18 | 2023-05-29 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法 |
| WO2019136179A1 (en) | 2018-01-03 | 2019-07-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| US12065476B2 (en) | 2018-06-15 | 2024-08-20 | Alpine Immune Sciences, Inc. | PD-1 variant immunomodulatory proteins and uses thereof |
| CA3106384A1 (en) * | 2018-11-02 | 2020-05-07 | Beijing Vdjbio Co., Ltd. | Modified ctla4 and methods of use thereof |
| JP7713886B2 (ja) | 2018-11-30 | 2025-07-28 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｄ８６バリアント免疫調節タンパク質およびその使用 |
| WO2020210596A1 (en) * | 2019-04-10 | 2020-10-15 | University Of Kentucky Research Foundation | Modified prostate apoptosis response-4 (par-4) polypeptide, and methods of production and use |
| CN115066494A (zh) * | 2020-01-11 | 2022-09-16 | 耶鲁大学 | 用于治疗、改善、和/或预防由DNAse1和/或DNAse1L3缺陷引起或与之相关的疾病或障碍的组合物和方法 |
| MX2022011892A (es) | 2020-03-26 | 2022-10-18 | Univ Vanderbilt | Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del sindrome respiratorio agudo grave (sars-cov-2). |
| CN115667292A (zh) * | 2020-04-06 | 2023-01-31 | 朗格生物技术公共公益股份有限公司 | 模块化合成受体和使用方法 |
| AU2021262609A1 (en) | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| WO2021226551A1 (en) | 2020-05-08 | 2021-11-11 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins and methods of use thereof |
| CN112661865B (zh) * | 2020-12-31 | 2026-04-03 | 厚朴生物科技（苏州）有限公司 | 针对新型冠状病毒的疫苗以及其应用 |
| WO2023057994A1 (en) * | 2021-10-08 | 2023-04-13 | Kashiv Biosciences, Llc | Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography |
| AU2022361768A1 (en) * | 2021-10-08 | 2024-05-02 | Kashiv Biosciences, Llc | Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography |
| AU2022414315A1 (en) * | 2021-12-17 | 2024-07-25 | Kashiv Biosciences, Llc | An improved assay method for determining the potency of recombinant protein |
| TW202342510A (zh) | 2022-02-18 | 2023-11-01 | 英商Ｒｑ生物科技有限公司 | 抗體 |
| EP4688856A1 (en) | 2023-04-03 | 2026-02-11 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0606217B2 (en) | 1991-06-27 | 2008-12-03 | Bristol-Myers Squibb Company | Ctl4a receptor, fusion proteins containing it and uses thereof |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| CA2257861A1 (en) * | 1996-06-14 | 1997-12-18 | Smithkline Beecham Corporation | Hexameric fusion proteins and uses therefor |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| PE20011338A1 (es) * | 2000-05-26 | 2002-01-13 | Bristol Myers Squibb Co | Moleculas mutantes de ctla4 solubles |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| WO2007007654A1 (ja) | 2005-07-07 | 2007-01-18 | Toshiba Lighting & Technology Corporation | 放電灯点灯装置および電球形蛍光ランプ |
| GB0620934D0 (en) * | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
| PT2222697E (pt) * | 2007-11-01 | 2013-02-15 | Perseid Therapeutics Llc | Polipeptídeos imunossupressores e ácidos nucleicos |
| PL3053932T3 (pl) | 2010-02-19 | 2021-03-08 | Xencor, Inc. | Nowe immunoadhezyny CTLA4-IG |
| EP2545073B1 (en) * | 2010-03-12 | 2015-09-30 | AbbVie Biotherapeutics Inc. | Ctla4 proteins and their uses |
| ES2777778T3 (es) * | 2012-05-11 | 2020-08-06 | Medimmune Ltd | Variantes de CTLA-4 |
-
2013
- 2013-03-11 ES ES17163638T patent/ES2777778T3/es active Active
- 2013-03-11 KR KR1020147031064A patent/KR102133060B1/ko active Active
- 2013-03-11 CN CN201380024763.3A patent/CN104302309B/zh active Active
- 2013-03-11 BR BR112014026718-9A patent/BR112014026718B1/pt active IP Right Grant
- 2013-03-11 JP JP2015511443A patent/JP6228971B2/ja active Active
- 2013-03-11 AU AU2013260172A patent/AU2013260172B2/en active Active
- 2013-03-11 MX MX2014013092A patent/MX355234B/es active IP Right Grant
- 2013-03-11 CN CN201710735648.7A patent/CN107540742B/zh active Active
- 2013-03-11 EP EP17163638.4A patent/EP3207938B1/en active Active
- 2013-03-11 PL PL17163638T patent/PL3207938T3/pl unknown
- 2013-03-11 HU HUE17163638A patent/HUE048925T2/hu unknown
- 2013-03-11 DK DK17163638.4T patent/DK3207938T3/da active
- 2013-03-11 US US14/399,685 patent/US9884902B2/en active Active
- 2013-03-11 EP EP13787673.6A patent/EP2863936A4/en not_active Withdrawn
- 2013-03-11 CA CA2868748A patent/CA2868748C/en active Active
- 2013-03-11 SG SG10201609447XA patent/SG10201609447XA/en unknown
- 2013-03-11 HK HK15110585.3A patent/HK1209644A1/xx unknown
- 2013-03-11 WO PCT/US2013/030179 patent/WO2013169338A1/en not_active Ceased
- 2013-03-11 MX MX2018003741A patent/MX385969B/es unknown
- 2013-03-11 RU RU2014150092A patent/RU2671465C2/ru active
- 2013-03-11 SG SG11201405968SA patent/SG11201405968SA/en unknown
-
2017
- 2017-12-21 US US15/850,990 patent/US20180208639A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tao et al. | Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines | |
| JP2011508604A5 (enExample) | ||
| Bermudez-Humaran et al. | An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci | |
| WO2009042570A3 (en) | Modified t cell receptors and related materials and methods | |
| JP2016532693A5 (enExample) | ||
| FI3393512T3 (fi) | Rsv f -proteiinin mutantteja | |
| JP2017538401A5 (enExample) | ||
| EP4609876A3 (en) | Anti-human papillomavirus 16 e7 t cell receptors | |
| JP2013537400A5 (enExample) | ||
| JP2018532382A5 (enExample) | ||
| EP4647442A3 (en) | T cell receptors recognizing mutated p53 | |
| JP2015532654A5 (enExample) | ||
| WO2007130455A3 (en) | Compositions and methods for treatment of non-hodgkins lymphoma | |
| JP2019522465A5 (enExample) | ||
| JP2016156828A5 (enExample) | ||
| IL278014B2 (en) | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use | |
| JP2013519721A5 (enExample) | ||
| JP2012095652A5 (enExample) | ||
| JP2016526909A5 (enExample) | ||
| JP2010519176A5 (enExample) | ||
| WO2011028344A3 (en) | Interleukin-1 receptor antagonist compositions and methods of making and using same | |
| JP2015511637A5 (enExample) | ||
| TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
| JP2009511000A5 (enExample) | ||
| RU2014150092A (ru) | Варианты ctla-4 |